ProPhase Labs provides update on progress, development for LB-1

ProPhase Labs provided an update regarding its progress and development strategy for Linebacker-1, LB-1. Linebacker is a small molecule, multi-kinase inhibitor that is being developed by the Company’s wholly owned subsidiary, ProPhase BioPharma, as a potential mono-therapy and co-therapy option for hard-to-treat cancers. Originally viewed as a co-therapy, the pre-clinical data generated has given PBIO reason to believe that LB-1 will also be very effective as a mono-therapy. In Q1 of 2023, ProPhase collaborated with Eurofins, a globally recognized leading drug discovery company, to execute an in-depth analysis of Linebacker-1 to determine how many cancer-relevant kinases were affected by Linebacker-1 out of a possible 468 enzymes. Importantly, the Eurofins analysis revealed several unique targets affected by Linebacker-1 that cancer research organizations highlight as critically important. In line with these impressive results, Linebacker-1 has demonstrated strong preclinical potential in a number of difficult diseases, including tough-to-treat lung and gastric cancers. As development continues, ProPhase intend to position Linebacker-1 as a potential new option for cancer patients suffering from a current lack of quality treatment options. The company intends to focus a majority of 2023 on developing a more in-depth understanding of the unique pathways ProPhase believes Linebacker may impact, as well as taking the necessary steps to meet the requirements for an IND submission to the FDA including: Cross-over analysis and machine learning to elucidate most affected signaling pathways; Maximum Tolerated Dose studies and safety confirmations; Opportunities for synergies with existing, but underwhelming, commercial medicines; Optimization of treatable neoplastic conditions within unsaturated areas